Recently, Huadong Medicine announced that it will invest no more than 396 million yuan to obtain a 60% stake in Wuhu Huaren Technology Co.
, Ltd.
(hereinafter referred to as "Huaren Technology") and become its controlling shareholder
.
Huaren Technology is in an advanced position in the field of nucleoside raw materials for small nucleic acid drugs and nucleotides (dNTPs) for diagnostic reagents, with about 1,500 products, mainly serving new drug research and development and production, biosynthesis, PCR amplification, gene Sequencing, diagnostic reagent production, medical testing, life science research and other professional departments
.
Regarding this acquisition, Huadong Medicine said that it is mainly because Huaren Technology has been deeply engaged in the technology and market in the nucleoside field for many years, and is a professional supplier of raw materials in the domestic nucleoside field; and Huadong Medicine is currently deploying the nucleoside business and is committed to building The whole industry chain ecosystem in the nucleoside field has become the world's leading core supplier of nucleic acid drug raw materials and services
.
According to public information, nucleoside drugs refer to biologically active drugs with nucleoside and deoxynucleoside structures
.
These drugs work through gene therapy, transferring specific genetic material (nucleotide fragments) into specific cells of patients for prevention and treatment purposes
.
Nucleoside and deoxynucleoside (acid) series compounds are mainly used in the field of medicine, and the market is also expanding while they are widely used
.
The data shows that from 2015 to 2018, the market size of China's nucleoside drug industry has grown from 28.
36 billion yuan to 55.
77 billion yuan, with an average annual compound growth rate of 14.
48%, of which nucleosides for liver diseases and anti-tumor nucleosides.
Drugs dominate
.
The industry predicts that the market size of China's nucleoside drug industry will exceed 70 billion yuan in 2022
.
At present, with the continuous expansion of the market scale of China's nucleoside drug industry, many domestic pharmaceutical companies have also begun to deploy this market
.
For example, Junshi Bio announced on October 4, 2021 that the company has reached a cooperation with Wangshan Wangshui Biopharmaceutical Co.
, Ltd.
and will jointly undertake the global clinical development and industrialization of the oral nucleoside anti-new coronavirus candidate drug VV116 work
.
In addition, as a pharmaceutical company specializing in the development of nucleoside (acid) APIs and pharmaceutical intermediates, Tuoxin Pharmaceutical has established a relatively complete product chain from basic products to high-end products.
Products include citicoline sodium, ribavirin, inosine, acyclovir, cytosine, 5-fluorocytosine, cytidine and other APIs and pharmaceutical intermediates, covering antiviral, antitumor and nervous system drugs field
.
It is understood that in 2021, Tuoxin Pharmaceutical will achieve a revenue of 502 million yuan, and a net profit of 66 million yuan after deducting non-return to the parent
.
Industry analysts believe that from a general perspective, the selection direction of Huadong Medicine's nucleoside raw materials is differentiated (small nucleic acid drugs, diagnostic raw materials) and more extensive
.
According to the 2021 financial report, there are currently a total of 45 R&D projects in the microbiology field of East China Pharmaceutical Industry, and the industrial microbiology sector has also achieved 418 million yuan.
Therefore, after the acquisition of Huaren, it is expected that the scale may exceed that of Tuoxin Pharmaceutical this year
.
